BR112022019454A2 - Composição compreendendo peptídeo vgll1 para tratamento de câncer - Google Patents

Composição compreendendo peptídeo vgll1 para tratamento de câncer

Info

Publication number
BR112022019454A2
BR112022019454A2 BR112022019454A BR112022019454A BR112022019454A2 BR 112022019454 A2 BR112022019454 A2 BR 112022019454A2 BR 112022019454 A BR112022019454 A BR 112022019454A BR 112022019454 A BR112022019454 A BR 112022019454A BR 112022019454 A2 BR112022019454 A2 BR 112022019454A2
Authority
BR
Brazil
Prior art keywords
composition
cancer treatment
cancer
vgll1 peptide
vgll1
Prior art date
Application number
BR112022019454A
Other languages
English (en)
Inventor
Sun Won Mi
Kyung Kim Bo
Im Joo-Young
Mi Kim Da
Original Assignee
Onecuregen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onecuregen Co Ltd filed Critical Onecuregen Co Ltd
Publication of BR112022019454A2 publication Critical patent/BR112022019454A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

COMPOSIÇÃO COMPREENDENDO PEPTÍDEO VGLL1 PARA TRATAMENTO DE CÂNCER. A presente invenção refere-se a um fragmento de peptídeo para tratamento de câncer, uma variante do mesmo e um uso do mesmo. Um fragmento de peptídeo de VGLL1 e/ou uma variante do mesmo de acordo com a presente invenção inibe a proliferação e invasão de células cancerígenas, exibindo assim um excelente efeito na prevenção e no tratamento do câncer.
BR112022019454A 2020-03-27 2021-03-22 Composição compreendendo peptídeo vgll1 para tratamento de câncer BR112022019454A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200037335 2020-03-27
PCT/KR2021/003496 WO2021194186A1 (ko) 2020-03-27 2021-03-22 Vgll1 펩타이드를 포함하는 암 치료용 조성물

Publications (1)

Publication Number Publication Date
BR112022019454A2 true BR112022019454A2 (pt) 2022-12-13

Family

ID=77892463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019454A BR112022019454A2 (pt) 2020-03-27 2021-03-22 Composição compreendendo peptídeo vgll1 para tratamento de câncer

Country Status (7)

Country Link
EP (1) EP4130025A4 (pt)
JP (1) JP7531931B2 (pt)
KR (2) KR20210120882A (pt)
CN (1) CN115298203A (pt)
AU (2) AU2021244056B2 (pt)
BR (1) BR112022019454A2 (pt)
WO (1) WO2021194186A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022220632A1 (ko) * 2021-04-15 2022-10-20 원큐어젠 주식회사 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393002A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2343602A1 (en) * 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
KR101714649B1 (ko) * 2013-10-30 2017-03-10 한국생명공학연구원 암 치료 또는 암 전이 타겟으로서 vgll1의 용도
WO2018067869A1 (en) * 2016-10-07 2018-04-12 Board Of Regents, The University Of Texas System Hla-restricted vgll1 peptides and use thereof
SG11202111744UA (en) * 2019-04-30 2021-11-29 Gigagen Inc Recombinant polyclonal proteins and methods of use thereof
WO2022220632A1 (ko) * 2021-04-15 2022-10-20 원큐어젠 주식회사 세포 투과 펩티드, 항암 펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2021194186A1 (ko) 2021-09-30
AU2021244056B2 (en) 2024-04-04
EP4130025A1 (en) 2023-02-08
JP2023520864A (ja) 2023-05-22
CN115298203A (zh) 2022-11-04
EP4130025A4 (en) 2024-05-29
KR20210120882A (ko) 2021-10-07
AU2021244056A1 (en) 2022-10-06
AU2024201112A1 (en) 2024-03-14
KR20240124255A (ko) 2024-08-16
JP7531931B2 (ja) 2024-08-13

Similar Documents

Publication Publication Date Title
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112022007677A2 (pt) L-asparaginase recombinante
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112021018687A2 (pt) Combinação de dose fixa de canabinoides e cogumelos medicinais para prevenção e tratamento de câncer, doenças inflamatórias ou inflamatórias imunomediadas
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
BR112022023013A2 (pt) Inibidores de mek para tratamento ou prevenção de infecções por coronavírus e/ou de tempestade de citocinas de covid-19
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
DOP2023000074A (es) Compuestos fosfolípidos y usos de estos
CO2022000270A2 (es) Inhibidores de enzimas
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
BR112022019454A2 (pt) Composição compreendendo peptídeo vgll1 para tratamento de câncer
BR112023000675A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
BR112021020605A2 (pt) Inibidor de mek para o tratamento de infecções virais e bacterianas
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
BR112022012283A2 (pt) Combinações
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
BR112021021299A2 (pt) Composições e métodos para tratamento de câncer
BR112021026193A2 (pt) Composições e métodos para tratar ou prevenir infecções oculares com filociclovir
BR112020024261B8 (pt) Composto de fórmula (ia) e composição farmacêutica
BR112023019407A2 (pt) Composições farmacêuticas compreendendo zolmitriptano

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]